

## Product datasheet for **AP33406PU-N**

### CD309 / VEGFR-2 / Flk-1 Rabbit Polyclonal Antibody

#### Product data:

Product Type:	Primary Antibodies
Applications:	FC, WB
Recommended Dilution:	<b>Western blot:</b> 1-5 µg/ml. <b>FACS:</b> 1-5 µg/ml.
Reactivity:	Mouse
Host:	Rabbit
Isotype:	IgG
Clonality:	Polyclonal
Immunogen:	Highly pure recombinant Mouse soluble endogenous Flk-1 (Ala20 – Pro673) (Cat.-No AP26035PU-N).
Specificity:	This antibody detects endogenous Mouse sVEGFR-2/Flk-1. Other species not tested.
Formulation:	PBS, pH 7.2 State: Purified State: Lyophilized purified IgG fraction
Reconstitution Method:	Restore in sterile water to a concentration of 0.1-1.0 mg/ml. Centrifuge vial prior to opening.
Purification:	Protein A Chromatography
Conjugation:	Unconjugated
Storage:	Store lyophilized at 2-8°C for 6 months or at -20°C long term. After reconstitution store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing.
Stability:	Shelf life: one year from despatch.
Database Link:	<a href="#">P35918</a>




[View online »](#)

**Background:**


Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not to our knowledge been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.

**Synonyms:**

VEGFR2, FLK1, KDR, VEGF Receptor 2

**Product images:**


Western analysis of recombinant Mouse sVEGFR-2/Flk-1 using a polyclonal antibody directed against recombinant Mouse Flk-1.



FACS analysis with primary mouse endothelial cells (SnoMec).